Keith Rubin is the founder of ILiAD Biotechnologies. ILiAD Biotechnologies has raised $215M in total funding. Latest round: Series B.
Keith Rubin, MD, is the CEO of ILiAD Biotechnologies, an advanced clinical-stage biotech company focused on preventing and treating diseases caused by Bordetella pertussis. He has led the company in developing its next-generation intranasal pertussis vaccine candidate, BPZE1, which is in Phase 3 development. Rubin presented clinical data from Phase 2B trials showing a 90% relative risk reduction in colonizing infection compared to placebo.
Full founder directory · Investor directory · Company funding database · Fundraising library